An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
Not Applicable
Completed
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- Registration Number
- NCT00002090
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Beth Israel Hosp
🇺🇸Boston, Massachusetts, United States
Bronx Veterans Affairs Med Ctr
🇺🇸Bronx, New York, United States
SUNY / Health Sciences Ctr at Syracuse
🇺🇸Syracuse, New York, United States
Ohio State Univ Hosp
🇺🇸Columbus, Ohio, United States
United States Air Force Med Ctr
🇺🇸Lackland Air Force Base, Texas, United States
Audie L Murphy Veterans Administration Hosp
🇺🇸San Antonio, Texas, United States
Beth Israel Hosp🇺🇸Boston, Massachusetts, United States